This review summarises the evidence relevant to the use of a quadrivalent inactivated influenza virus vaccine produced using a continuous mammalian cell line (Flucelvax® Quad) for the prevention of seasonal influenza in adults and children aged ≥6 months, including its benefits relative to egg based quadrivalent influenza vaccines. This review is sponsored by CSL Seqirus (NZ) Ltd.
Please login below to download this issue (PDF)